Why GW Pharmaceuticals Stock Rocketed 40.5% in February
Posted on Friday March 05, 2021
Shares of GW Pharmaceuticals (NASDAQ: GWPH) rose 40.5% in February, according to data provided by S&P Global Market Intelligence. The bulk of the move came on Feb. 3 when Jazz Pharmaceuticals (NASDAQ: JAZZ) announced it would be purchasing GW for $7.2 billion, or the equivalent of $220 per share, made up of $200 per share in cash and $20 in Jazz stock. GW has the only drug made from cannabis, the emerging blockbuster Epidiolex.
Investors: The Marijuana Boom Is Now
Posted on Wednesday March 03, 2021
Marijuana will provide the basis for many of tomorrow's blockbuster drugs. David Borun shows you how to invest in this burgeoning industry.
The 10 Best Marijuana Stocks in February
Posted on Wednesday March 03, 2021
Following a more than one-year downtrend, there's no longer any doubt about it: Marijuana stocks are back in a big way. The excitement surrounding pot stocks was readily evident when analyzing their monthly returns in February. Whereas the benchmark S&P 500 ended last month higher by 2.6%, 10 marijuana stocks crossed the finish line with a gain of at least 20%.
GW Pharmaceuticals' Epidyolex Wins EU Positive Opinion For Seizures Disorder
Posted on Friday February 26, 2021
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for GW Pharmaceuticals Plc's (NASDAQ: GWPH) Epidyolex (cannabidiol). It is an adjunctive treatment of seizures associated with Tuberous Sclerosis Complex (TSC) for patients two years of age and older. TSC is characterized by benign tumors that grow in the body's vital organs, including the brain, skin, heart, eyes, kidneys, and lungs, and in which epilepsy is the most common neurological feature. The condition is typically diagnosed in childhood. The EMA approved GW's cannabidiol oral solution in September 2019 as adjunctive therapy for seizures associated with Lennox-Gastaut Syndrome or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older. Price Action: GWPH is up 0.1% at $215.05 in market trading hours on the last check Friday. See more from BenzingaClick here for options trades from BenzingaAssembly Bio/Arbutus Bio Start Testing Vebicorvir/AB-729 Triplet Therapy In HBV InfectionGlaukos' iLink Therapy Meets Primary Endpoint In Late-Stage Vision Disorder Study© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
